Octagon Capital Advisors LP

Octagon Capital Advisors LP reported 27 holdings worth US$1.11B as of Jun 30, 2026 (Form 13F)

As of Jun 30, 2026 · Filed Aug 14, 2026

Octagon Capital Advisors LP reported 27 holdings worth US$1.11B as of Jun 30, 2026. Largest: Dianthus Therapeutics, Inc., Definium Therapeutics, Inc. and Abivax Sa. Filed Aug 14, 2026 (Form 13F).

Holdings
27
Value as reported
US$1.11B

The filing in full

CompanySharesValue as reported% of portfolio
Dianthus Therapeutics, Inc.1.84MUS$180M16.1%
Definium Therapeutics, Inc.2.95MUS$139M12.5%
Abivax Sa993KUS$132M11.9%
Cogent Biosciences, Inc.2.35MUS$90.9M8.2%
Alumis Inc.2.83MUS$79.7M7.2%
Arrivent Biopharma, Inc.1.97MUS$68.5M6.2%
Taysha Gene Therapies, Inc.9.69MUS$66M5.9%
Bioage Labs, Inc.1.75MUS$42.8M3.9%
Mirum Pharmaceuticals, Inc.339KUS$39.7M3.6%
Kymera Therapeutics, Inc.310KUS$35.5M3.2%
Aktis Oncology, Inc.961KUS$31M2.8%
Xenon Pharmaceuticals Inc.490KUS$29.6M2.7%
Palisade Bio, Inc.10.3MUS$21.5M1.9%
Ocular Therapeutix, Inc.2.08MUS$20.4M1.8%
Disc Medicine, Inc.270KUS$19.7M1.8%
Summit Therapeutics Inc.1.25MUS$18.2M1.6%
Precision Biosciences, Inc.1.35MUS$10.6M0.95%
Dbv Technologies Sa574KUS$9.42M0.85%
Sensei Biotherapeutics, Inc.361KUS$9.03M0.81%
Gyre Therapeutics, Inc.954KUS$6.29M0.57%
Trevi Therapeutics, Inc.315KUS$5.87M0.53%
Unicycive Therapeutics, Inc.1MUS$4.69M0.42%
Context Therapeutics Inc.3.05MUS$1.69M0.15%
Gossamer Bio, Inc.7.75MUS$1.28M0.11%
Terns Pharmaceuticals, Inc.0US$00.00%
Bridgebio Oncology Therapeutics, Inc.0US$00.00%
Evommune, Inc.0US$00.00%
Kalvista Pharmaceuticals, Inc.0US$00.00%
Lexeo Therapeutics, Inc.0US$00.00%
Perspective Therapeutics, Inc.0US$00.00%

Source

View original at SEC

Related